Conditions: Gout
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 143
Healthy volunteers: no

Brief summary:
This study will assess the serum uric acid lowering effects and safety of lesinurad over a long-term timeframe.

Detailed description:
This is a Phase 3, open-label, uncontrolled, extension study to assess the long-term efficacy and safety of lesinurad monotherapy in subjects who completed the double-blind treatment period in Study RDEA594-303.

Arms:
arm 1: None

Interventions: intervention 1: lesinurad
Intervention descriptions: intervention 1: Tablets, 400 mg QD

Protocol document: